In a research report released Friday, William Blair analyst Y Katherine Xu reiterated an Outperform rating on Synthetic Biologics Inc (NYSEMKT:SYN) with a $12 …
In a research report released today, H.C.
Maxim’s healthcare analyst Jason Kolbert came out today with a research note on Synthetic Biologics Inc (NYSE MKT:SYN), downgrading shares from Buy to Hold, and reiterating $3 …
